Retatrutide is an unapproved investigational triple agonist (GLP-1, GIP, glucagon receptors) not licensed by the MHRA, EMA, or FDA for routine clinical use
The decision to continue, adjust, or discontinue therapy should be based on objective body composition measurements (DEXA scans, circumference measurements), achievement of fat loss goals, tolerance and side effect profile, and physician assessment of metabolic markers
A 2006 Phase I trial of CJC-1295 reported no serious adverse events across a small number of subjects, but it was a safety study, not an outcomes trial, and there are no large trials showing it does what enthusiasts hope
Post-Treatment Care: Following your B12 Injection, we provide guidance on post-treatment care
What is BPC 157 and how does it work
Quick Answer: How Long Do Peptides Last in the Fridge